# Diagnosis and genetic analysis of Gaucher disease in a pediatric case: a case report

## TL;DR

A 2-year-old child was diagnosed with Gaucher disease through blood tests, imaging, and genetic analysis, and is undergoing enzyme replacement therapy.

## Contribution

This case report confirms a rare Gaucher disease mutation and highlights the importance of genetic testing for diagnosis.

## Key findings

- The child had reduced GBA activity and elevated Lyso-Gb1 levels, confirming Gaucher disease.
- A homozygous GBA gene mutation c.1448T>C(p.Leu483Pro) was identified in the child.
- Both parents were heterozygous carriers of the same mutation, supporting autosomal recessive inheritance.

## Abstract

A 2-year-old patient was admitted to our hospital with hepatosplenomegaly as the prominent clinical feature. Peripheral blood analysis during hospitalization revealed trilineage cytopenia. Bone marrow cytology examination demonstrated abundant suspected Gaucher cells. Full-spine MRI exhibited widening of the distal femoral metaphysis with an “Erlenmeyer flask deformity.” Subsequent enzymatic and genetic evaluations for Gaucher disease (GD) confirmed reduced β-glucocerebrosidase (GBA) activity, significantly elevated glucosylsphingosine (Lyso-Gb1) levels, and a homozygous missense mutation in the GBA gene c. 1448T>C(p.Leu483Pro). Genetic testing of the parents revealed both were heterozygous carriers of the same mutationc. 1448T>C(p.Leu483Pro), confirming the diagnosis of GD in the child with an autosomal recessive inheritance pattern. GD typically presents in childhood with hepatosplenomegaly, anemia, and thrombocytopenia. Given its rarity and nonspecific clinical manifestations, bone marrow cytology and imaging studies may provide diagnostic clues, but definitive diagnosis requires confirmation through β-glucocerebrosidase activity assays and genetic testing. Enzyme replacement therapy (ERT) is currently the primary treatment modality. The child is receiving regular intravenous infusions of imiglucerase at our hospital.